Human papillomavirus (HPV), HPV-associated oropharyngeal cancer, and HPV vaccine in the United States-Do we need a broader vaccine policy?

Vaccine

Volumn 31, Issue 47, 2013, Pages 5500-5505

  Osazuwa Peters, N ^a  

^a SAINT LOUIS UNIVERSITY   (United States)

Author keywords

HPV vaccine; HPV vaccine mandates; HPV associated cancers; HPV associated oropharyngeal cancer; Human papillomavirus (HPV); School entry requirements

Indexed keywords

WART VIRUS VACCINE;

CANCER PREVENTION; COST EFFECTIVENESS ANALYSIS; DIPHTHERIA; DRUG COST; DRUG SAFETY; HEALTH CARE POLICY; HEALTH ECONOMICS; HEALTH EDUCATION; HEALTH INSURANCE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; INFECTION CONTROL; MEASLES; MORBIDITY; MORTALITY; MUMPS; OROPHARYNX CANCER; PAPILLOMAVIRUS INFECTION; PARENT; PERTUSSIS; POLIOMYELITIS; PRIORITY JOURNAL; REVIEW; RUBELLA; SCHOOL; SCHOOL HEALTH SERVICE; SEXUALLY TRANSMITTED DISEASE; SMALLPOX; TETANUS; UNITED STATES; UTERINE CERVIX CANCER; VACCINATION;

HPV VACCINE; HPV VACCINE MANDATES; HPV-ASSOCIATED CANCERS; HPV-ASSOCIATED OROPHARYNGEAL CANCER; HUMAN PAPILLOMAVIRUS (HPV); SCHOOL-ENTRY REQUIREMENTS;

HEALTH POLICY; HUMANS; IMMUNIZATION PROGRAMS; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UNITED STATES;

EID: 84886797871     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.09.031     Document Type: Review

References (83)

1. World Health Organization. Human Papillomavirus. [accessed 21.03.13]. http://www.who.int/vaccines/en/hpvrd.shtml.
2. World Health Organization. Human Papillomavirus. [accessed 26.03.13]. http://www.who.int/nuvi/hpv/en.
3. Garner E.I. Cervical cancer: disparities in screening, treatment, and survival. Cancer Epidemiol Biomarkers Prev 2003, 12:242s-247s.
4. Jemal A., Center M.M., DeSantis C., Ward E.M. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010, 19:1893-1907.
5. Gillison M.L., Koch W.M., Capone R.B., Spafford M., Westra W.H., Wu L., et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000, 92:709-720.
6. Chaturvedi A.K., Engels E.A., Pfeiffer R.M., Hernandez B.Y., Xiao W., Kim E., et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011, 29:4294-4301.
7. Sturgis E.M., Ang K.K. The epidemic of HPV-associated oropharyngeal cancer is here: is it time to change our treatment paradigms. J Natl Compr Canc Netw 2011, 9:665-673.
8. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol 2009, 45:309-316.
9. Kreimer A.R., Clifford G.M., Boyle P., Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005, 14:467-475.
10. Ryerson A.B., Peters E.S., Coughlin S.S., Chen V.W., Gillison M.L., Reichman M.E., et al. Burden of potentially human papillomavirus-associated cancers of the oropharynx and oral cavity in the US, 1998-2003. Cancer 2008, 113(Suppl. 10):2901-2909.
11. Centers for Disease Control and Prevention (CDC). Human Papillomavirus (HPV). [accessed 28.03.13]. http://www.cdc.gov/hpv/.
12. Gillison M.L., Broutian T., Pickard R.K., Tong Z.Y., Xiao W., Kahle L., et al. Prevalence of oral HPV infection in the United States: 2009-2010. JAMA 2012, 307(7):693-703.
13. Dunne E.F., Unger E.R., Sternberg M., McQuillan G., Swan D.C., Patel S.S., et al. Prevalence of HPV infection among females in the United States. JAMA 2007, 297:813-819.
14. Moscicki A.B. Impact of HPV infection in adolescent populations. J Adolesc Health 2005, 37(Suppl. 6):3-9.
15. Marur S., D'Souza G., Westra W.H., Forastiere A.A. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 2010, 11:781-789.
16. Morse D.E., Kerr A.R. Disparities in oral and pharyngeal cancer incidence, mortality and survival among black and white Americans. J Am Dent Assoc 2006, 137:203-212.
17. National Conference of State legislatures. HPV vaccine: state legislation and statutes. [accessed 15.11.12]. http://www.ncsl.org/issues-research/health/hpv-vaccine-state-legislation-and-statutes.aspx.
18. Harris V, Jackson RS, Ward M, Cardarelli KM, Kurian A, Raines A, et al. The HPV vaccine: a look at both sides of the debate. [accessed 17.11.12]. http://www.centerforcommunityhealth.org/.../HPVBriefFinal-NoBlank.pdf.
19. Reiter P.L., Stubbs B., Panozzo C.A., Whitesell D., Brewer N.T. HPV and HPV vaccine education intervention: effects on parents, healthcare staff, and school staff. Cancer Epidemiol Biomarkers Prev 2011, 20:2354-2361.
20. Davis K., Dickman E.D., Ferris D., Dias J.K. Human papillomavirus vaccine acceptability among parents of 10- to 15-year-old adolescents. J Low Genit Tract Dis 2004, 8:188-194.
21. Wetzel C., Tissot A., Kollar L.M., Hillard P.A., Stone R., Kahn J.A. Development of an HPV educational protocol for adolescents. J Pediatr Adolesc Gynecol 2007, 20:281-287.
22. Beatty B.G., O'Connell M., Ashikaga T., Cooper K. Human papillomavirus (HPV) education in middle and high schools of Vermont. J Sch Health 2003, 73:253-257.
23. Friedman A.L., Shepeard H. Exploring the knowledge, attitudes, beliefs, and communication preferences of the general public regarding HPV: findings from CDC focus group research and implications for practice. Health Educ Behav 2007, 34:471-485.
24. Kirby D. Comprehensive school health and the larger community: issues and a possible scenario. J School Health 1990, 60:170-177.
25. Lefkowitz E.S., Romo L.F., Corona R., Au T.K., Sigman M. How Latino American and European American adolescents discuss conflicts, sexuality, and AIDS with their mothers. Dev Psychol 2000, 36:315-325.
26. Akers A.Y., Holland C.L., Bost J. Interventions to improve parental communication about sex: a systematic review. Pediatrics 2011, 127:494-510.
27. Pluhar E.I., Kuriloff P. What really matters in family communication about sexuality? A qualitative analysis of affect and style among African American mothers and adolescent daughters. Sex Educ 2004, 4:303-321.
28. Marsman J.C., Herold E.S. Attitudes toward sex education and values in sex education. Fam Relat 1986, 35:357-361.
29. Burgess V., Dziegielewski S.F., Green C.E. Improving comfort about sex communication between parents and their adolescents: practice-based research within a teen sexuality group. Brief Treat Crisis Interv 2005, 5:379-390.
30. Constantine N.A., Jerman P., Huang A.X. California parents' preferences and beliefs regarding school-based sex education policy. Perspect Sex Reprod Health 2007, 39:167-175.
31. Eaton D.K., Kann L., Kinchen S., Shanklin S., Flint K.H., Hawkins J., et al. Youth risk behavior surveillance-United States. MMWR Surveill Summ 2012 2011, 61:1-162.
32. Arbyn M., Anttila A., Jordan J., Ronco G., Schenck U., Segnan N., et al. European guidelines for quality assurance in cervical cancer screening-summary document. Ann Oncol 2010, 21:448-458.
33. Akers A.Y., Newmann S.J., Smith J.S. Factors underlying disparities in cervical cancer incidence, screening, and treatment in the United States. Curr Probl Cancer 2007, 31:157-181.
34. Lingen M.W., Kalmar J.R., Karrison T., Speight P.M. Critical evaluation of diagnostic aids for the detection of oral cancer. Oral Oncol 2008, 44:10-22.
35. Giuliano A.R., Palefsky J.M., Goldstone S., Moreira E.D., Penny M.E., Aranda C., et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med 2011, 364:401-411.
36. Gillison M.L., Chaturvedi A.K., Lowy D.R. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer 2008, 113(Suppl. 10):3036-3046.
37. Herrero R., Quint W., Hildesheim A., Gonzalez P., Struijk L., Katki H.A., et al. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS ONE 2013, 8:e68329.
38. Saslow D., Castle P.E., Cox J.T., Davey D.D., Einstein M.H., Ferris D.G., et al. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 2007, 57:7-28.
39. Ohri L.K. HPV vaccine: immersed in controversy. Ann Pharmacother 2007, 41:1899-1902.
40. Schwartz J., Caplan A., Faden R., Sugarman J. Lessons from the failure of human papillomavirus vaccine state requirements. Clin Pharmacol Ther 2007, 82:760-763.
41. Balog J.E. The moral justification for a compulsory human papillomavirus vaccination program. Am J Public Health 2009, 99:616-622.
42. Stern A.M., Markel H. The history of vaccines and immunization: familiar patterns, new challenges. Health Aff 2005, 24:611-621.
43. Orenstein W.A., Hinman A.R. The immunization system in the United States-the role of school immunization laws. Vaccine 1999, 17(Suppl. 3):S19-S24.
44. Malone K.M., Hinman A.R. Vaccination mandates: the public health imperative and individual rights. Law in public health practice 2003, 262-284. Oxford University Press, New York, NY. R.A. Goodman, M.A. Rothstein, R.E. Hoffman (Eds.).
45. Dempsey A.F., Mendez D. Examining future adolescent human papillomavirus vaccine uptake, with and without a school mandate. J Adolesc Health 2010, 47:242-248. e246.
46. Arbyn M., de Sanjosé S., Saraiya M., Sideri M., Palefsky J., Lacey C., et al. EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease. Int J Cancer 2012, 131:1969-1982.
47. Donovan B., Franklin N., Guy R., Grulich A.E., Regan D.G., Ali H., et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 2011, 11:39-44.
48. Brotherton J.M., Fridman M., May C.L., Chappell G., Saville A.M., Gertig D.M. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011, 377:2085-2092.
49. Bosch F.X., de Sanjose S., Castellsague X. The prospects of HPV vaccination in cervical cancer prevention: results of a new independent trial. Cancer Discov 2011, 1:377-380.
50. Binagwaho A., Wagner C.M., Gatera M., Karema C., Nutt C.T., Ngabo F. Achieving high coverage in Rwanda's national human papillomavirus vaccination programme. Bull World Health Org 2012, 90:623-628.
51. Gostin L.O., DeAngelis C.D. Mandatory HPV vaccination. JAMA 2007, 297:1921-1923.
52. Stewart A. Childhood vaccine and school entry laws: the case of HPV vaccine. Public Health Rep 2008, 123:801.
53. Recommendations on the use of quadrivalent Human Papillomavirus Vaccine in males-Advisory Committee on Immunization Practices (ACIP) 2011, http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6050a3.htm [accessed 15.11.12].
54. Giuliano A.R., Anic G., Nyitray A.G. Epidemiology and pathology of HPV disease in males. Gynecol Oncol 2010, 117(Suppl. 2):15-19.
55. Centers for Disease Control and Prevention. HPV and men-fact sheet. Available at [accessed 27.04.13]. http://www.cdc.gov/std/hpv/stdfact-hpv-and-men.htm.
56. Johnson L.G., Madeleine M.M., Newcomer L.M., Schwartz S.M., Daling J.R. Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000. Cancer 2004, 101:281-288.
57. Vamos C.A., McDermott R.J., Daley E.M. The HPV vaccine: framing the arguments FOR and AGAINST mandatory vaccination of all middle school girls. J Sch Health 2008, 78:302-309.
58. Gerend M.A., Barley J. Human papillomavirus vaccine acceptability among young adult men. Sex Transm Dis 2009, 36:58-62.
59. Giuliano A.R. Human papillomavirus vaccination in males. Gynecol Oncol 2007, 107:24-26.
60. Ault K.A. Human papillomavirus vaccines and the potential for cross-protection between related HPV types. Gynecol Oncol 2007, 107:31-33.
61. Centers for Disease Control and Prevention (CDC) Ten great public health achievements-United States, 1900-1999. MMWR Morb Mortal Wkly Rep 1999, 48:241-248.
62. Salmon D.A., Teret S.P., MacIntyre C.R., Salisbury D., Burgess M.A., Halsey N.A. Compulsory vaccination and conscientious or philosophical exemptions: past, present, and future. Lancet 2006, 367:436-442.
63. Albert M.R., Ostheimer K.G., Breman J.G. The last smallpox epidemic in Boston and the vaccination controversy, 1901-1903. N Engl J Med 2001, 344:375-379.
64. Gross C.P., Sepkowitz K.A. The myth of the medical breakthrough: smallpox, vaccination, and Jenner reconsidered. Int J Infect Dis 1998, 3:54-60.
65. Mercer A.J. Smallpox and epidemiological-demographic change in Europe: the role of vaccination. Popul Stud (Camb) 1985, 39:287-307.
66. Bonanni P. Demographic impact of vaccination: a review. Vaccine 1999, 17:120-125.
67. Ritvo P., Wilson K., Willms D., Upshur R., Goldman A., Kelvin D., et al. Vaccines in the public eye. Nat Med 2005, 11:20-24.
68. Zimmerman R.K. Ethical analysis of HPV vaccine policy options. Vaccine 2006, 24:4812-4820.
69. Osazuwa-Peters N. Determinants of health disparities: the perennial struggle against polio in Nigeria. Int J Prev Med 2011, 2:117-121.
70. Hu D., Goldie S. The economic burden of noncervical human papillomavirus disease in the United States. Am J Obstet Gynecol 2008, 198:500e1-500e7.
71. The value of HPV vaccination. Nat Med 2012, 18:28-29.
72. Palefsky J.M. Human papillomavirus-related disease in men: not just a women's issue. J Adolesc Health 2010, 46:12-19.
73. Villa L.L. Prophylactic HPV vaccines: reducing the burden of HPV-related diseases. Vaccine 2006, 24:23-28.
74. Daley M.F., Liddon N., Crane L.A., Beaty B.L., Barrow J., Babbel C., et al. A national survey of pediatrician knowledge and attitudes regarding human papillomavirus vaccination. Pediatrics 2006, 118:2280-2289.
75. Dempsey A.F., Davis M.M. Overcoming barriers to adherence to HPV vaccination recommendations. Am J Manag Care 2006, 12(Suppl. 17):484-491.
76. Fang C.Y., Coups E.J., Heckman C.J. Behavioral correlates of HPV vaccine acceptability in the 2007 Health Information National Trends Survey (HINTS). Cancer Epidemiol Biomarkers Prev 2010, 19:319-326.
77. Haug C. The risks and benefits of HPV vaccination. JAMA 2009, 302:795-796.
78. Slade B.A., Leidel L., Vellozzi C., Woo E.J., Hua W., Sutherland A., et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009, 302:750-757.
79. Colgrove J. The ethics and politics of compulsory HPV vaccination. N Engl J Med 2006, 355:2389-2391.
80. Ciolli A. Mandatory school vaccinations: the role of tort law. Yale J Biol Med 2008, 81:129-137.
81. Tomljenovic L., Shaw C.A. Too fast or not too fast: the FDA's approval of Merck's HPV vaccine Gardasil. J Med Ethics 2012, 40:673-681.
82. National Center for Immunization and Respiratory Disease. Vaccines and preventable diseases: HPV vaccine - questions & answers. [accessed 27.03.13]. http://www.cdc.gov/vaccines/vpd-vac/hpv/vac-faqs.htm.
83. U.S. Department of Health and Human Services. Office of Disease Prevention and Health Promotion. Healthy People 2020. [accessed 21.03.12]. http://www.healthypeople.gov/2020/.../objectiveslist.aspx%3Ftopicid=32.